NEW YORK, July 14, 2015 /PRNewswire/ -- The global mycoplasma testing market is expected to reach $613.49 million by 2019 from $340.29 million in 2014, growing at a CAGR of 12.51% between 2014 and 2019. The mycoplasma testing product segments included in this report are instruments, kits & reagents, and services. The kits & reagents segment is further divided on the basis of type into stains, elimination kits, PCR assays, nucleic acid detection kits, standards & controls and other kits & reagents. The technology segments included are microbial culture techniques, DNA staining, PCR, ELISA, direct assay, indirect assay and enzymatic methods. On the basis of applications, the report is segmented into cell line testing, virus testing, end of production cells testing and other applications. The cell line testing applications had the largest share of the mycoplasma testing market in 2014. The cell line testing application is expected to be one of the fastest growing applications between 2014 and 2019.
The geographic segments included in this report are North America, Europe, Asia and Rest of the World (RoW). The geographic analysis reveals that North America accounted for the largest share in the global mycoplasma testing market in 2014. Asia regional segment, on the other hand, is expected to register a faster growth from 2014 to 2019, due to the increasing demand for mycoplasma testing and drug discovery and research from this region.
The key driver for this market is increased research funding by government. Furthermore, growing biotechnology and pharmaceutical companies to increase R&D activities and innovations in life science research and will aid the growth of the global mycoplasma testing market.
A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global mycoplasma testing market and its sub-segments. Secondary information was used to identify the overall revenues, geographic reach, and product portfolios of the market players. Estimates of their mycoplasma testing product segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine percentage shares of each sub segment and the relative differences in the growth rates.
The report provides qualitative insights about key market shares, growth rates, and market drivers for all important sub segments. It maps the market sizes and growth rates of each sub segment and identifies the segments poised for rapid growth in each of the geographic segments. The report also includes company profiles of the market leaders. These company profiles include financial performances, product portfolios, and market developments for each company. The report also provides a competitive landscape of the mycoplasma testing market. The competitive landscape covers the growth strategies adopted by the industry players over the last four years. It also includes analysis of industry developments like expansions, agreements and partnerships, mergers and acquisitions and new product launches.
Reasons to Buy the Report :
The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.
The report provides insights on the following:
• Product Development: Product portfolios of the top players in the mycoplasma testing market.
• Competitive Assessment: In-depth assessment of the market shares, strategies, geographic and business segments, and product portfolios of the leading players in the mycoplasma testing market.
• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various mycoplasma testing products across geographies.
Read the full report: http://www.reportlinker.com/p02978960-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001